Aspire Biopharma Holdings (ASBP) Operating Expenses (2021 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Operating Expenses of $1.7 million for Q1 2026, down 89.38% year-over-year from $15.6 million in Q1 2025, and down 10.63% quarter-over-quarter from $1.8 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Operating Expenses (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Operating Expenses for 6 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 89.38% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $5.4 million (down 67.06% YoY), while the FY2025 annual figure was $19.4 million, up 1498.12% from the prior year.
- Operating Expenses declined to $1.7 million in Q1 2026 per ASBP's latest filing, from $1.8 million in the prior quarter.
- Across five years, Operating Expenses topped out at $15.6 million in Q1 2025 and bottomed at $96923.0 in Q2 2024.
- Historically, Operating Expenses has averaged $1.4 million across 5 years, with a median of $324565.0 in 2023.
- Annual changes were most pronounced in 2022 — Operating Expenses soared 41493.38% — and 2026, when it tumbled 89.38%.
- Aspire Biopharma Holdings' Operating Expenses stood at $314030.0 in 2022, then rose by 28.21% to $402615.0 in 2023, then surged by 65.85% to $667722.0 in 2024, then soared by 176.83% to $1.8 million in 2025, then fell by 10.63% to $1.7 million in 2026.
- Business Quant data shows ASBP's Operating Expenses at $1.7 million in Q1 2026, $1.8 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 541.02 Mn |
| 10 | Aspire Biopharma Holdings | 8.46 Mn | -3.71 Mn | -30,086.00 | 2.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.65 Mn |
| Mar 31, 2026 | 1.65 Mn |
| Dec 31, 2025 | 1.85 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 799,890.00 |
| Mar 31, 2025 | 15.56 Mn |
| Dec 31, 2024 | 667,722.00 |
| Sep 30, 2024 | 215,256.00 |
| Jun 30, 2024 | 96,923.00 |
| Mar 31, 2024 | 230,970.00 |
| Dec 31, 2023 | 402,615.00 |
| Sep 30, 2023 | 324,742.00 |
| Jun 30, 2023 | 288,246.00 |
| Mar 31, 2023 | 324,565.00 |
| Dec 31, 2022 | 314,030.00 |
| Sep 30, 2022 | 255,257.00 |
| Jun 30, 2022 | 297,840.00 |
| Mar 31, 2022 | 109,219.00 |
| Dec 31, 2021 | 755.00 |
| Sep 30, 2021 | 15,310.00 |